Artia Global Partners LP Buys Shares of 229,785 Arcellx, Inc. (NASDAQ:ACLX)

Artia Global Partners LP purchased a new position in Arcellx, Inc. (NASDAQ:ACLX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 229,785 shares of the company’s stock, valued at approximately $17,622,000. Arcellx comprises approximately 6.3% of Artia Global Partners LP’s portfolio, making the stock its 4th largest position.

Other large investors have also recently made changes to their positions in the company. Headlands Technologies LLC acquired a new stake in shares of Arcellx in the fourth quarter valued at approximately $41,000. KBC Group NV increased its stake in shares of Arcellx by 37.3% in the 4th quarter. KBC Group NV now owns 1,388 shares of the company’s stock worth $106,000 after acquiring an additional 377 shares during the last quarter. Avanza Fonder AB purchased a new position in shares of Arcellx during the 4th quarter worth $184,000. Kazazian Asset Management LLC acquired a new position in shares of Arcellx during the 4th quarter valued at about $204,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Arcellx in the fourth quarter valued at about $214,000. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Arcellx

In other Arcellx news, insider Christopher Heery sold 10,155 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $63.79, for a total value of $647,787.45. Following the sale, the insider now owns 37,486 shares of the company’s stock, valued at $2,391,231.94. This trade represents a 21.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kavita Patel sold 1,500 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $64.57, for a total value of $96,855.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,455 shares of company stock worth $3,408,458. Company insiders own 6.24% of the company’s stock.

Arcellx Price Performance

Shares of ACLX stock opened at $63.71 on Friday. The firm’s 50-day moving average is $64.76 and its two-hundred day moving average is $74.76. Arcellx, Inc. has a 12 month low of $47.88 and a 12 month high of $107.37. The company has a market capitalization of $3.51 billion, a PE ratio of -89.73 and a beta of 0.33.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The business had revenue of $15.27 million during the quarter, compared to analysts’ expectations of $27.42 million. Sell-side analysts forecast that Arcellx, Inc. will post -1.58 EPS for the current year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).